Latest Hotspot

Domain Therapeutics and Chime Biologics Ink Deal to Advance CCR8 Antibody for Cancer Immunotherapy

15 March 2024
3 min read

Domain Therapeutics and Chime Biologics have publicized the execution of a contract for manufacturing services. The agreement specifies the fabrication of Domain Therapeutics' leading anti-CCR8 monoclonal antibody, known as DT-7012, which targets the depletion of Tregs. The goal of this production stage is to offer a potent treatment option to the global cancer patient community.

👇Explore more about this drug by clicking the image below. Gain detailed insights into its R&D Status, Core Patent, Clinical Trials and Global Approval Status. Stay informed and updated.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

Pursuant to the contractual obligations, Chime Biologics is committed to facilitating consistent cellular line creation and the production of the DT-7012 candidate, bolstering the upcoming clinical assessments in key nations. Chime Biologics boasts its premier worldwide plant, equipped with disposable bioprocessing apparatus that aligns with the universal cGMP requisites and boasts a robust history of satisfactory audits.

DT-7012 is an innovative monoclonal antibody targeted against CCR8 that significantly depletes Tregs present within tumors, these cells being prominent in suppressing immune functions. The solo application of the anti-CCR8 monoclonal antibody has revealed a distinctive capability to counteract tumors.

When juxtaposed with peer CCR8-targeting antibodies currently undergoing clinical trials, DT-7012 has manifested unparalleled potential, forging a path for successful GPCR-oriented immunotherapy approaches designed to invigorate the immune response against tumors in patients who have not benefited from alternative treatments. It is anticipated that Phase I clinical evaluations of DT-7012 will commence at the onset of 2025 for solid malignancies and midway through 2025 for cutaneous T-cell lymphoma.

Dr. Jimmy Wei, holding the presidential position at Chime Biologics, stated, “Anticipating the advancement of this pivotal alliance is exciting, blending the expertise of Domain in pioneering its anti-CCR8 antibody candidate with Chime Biologics' proficiency from CLD to full-scale production, a significant move in progressing DT-7012's application across a spectrum of cancer types.”

Expressing views on the collaboration, Stephan Schann, the Chief Scientific Officer at Domain Therapeutics, communicated: “The groundbreaking GPCR-focused immunotherapeutic we're developing holds extensive promise in unleashing the capabilities of the immune system to combat oncological conditions, potentially benefiting a global patient demographic. At Domain, we hold an unwavering commitment to precision in research and trailblazing innovation, and we actively seek cooperative endeavors with entities that echo our earnest commitment to propel the frontiers of immuno-oncology.”

👇Explore the latest research progress on drug-related developments, indications, therapeutic organizations, clinical trials, results, and patents by clicking on the targeted picture link below. Unfold a world of comprehensive information on this target in just a click!

图形用户界面, 文本, 应用程序

描述已自动生成

According to the data provided by the Synapse Database, As of March 13, 2024, there are 34 investigational drugs for the CCR8 target, including 26 indications, 36 R&D institutions involved, with related clinical trials reaching 22, and as many as 2418 patents.

DT-7012 is a monoclonal antibody that targets CCR8 and aims to treat neoplasms. It is currently in the preclinical phase, and further research is needed to assess its potential as a therapeutic option for neoplasms.

图形用户界面, 文本, 应用程序

描述已自动生成

The Synapse User's Toolkit: Tips for Searching Glipizide
Drug Insights
2 min read
The Synapse User's Toolkit: Tips for Searching Glipizide
15 March 2024
Glipizide, a small yet powerful drug from Pfizer Inc., effectively combats hyperglycemia and type 2 diabetes.
Read →
MRT-8102 Preclinical Trials: Exploring Monte Rosa's Innovative NEK7-Targeted Molecular Glue Degrader
Latest Hotspot
3 min read
MRT-8102 Preclinical Trials: Exploring Monte Rosa's Innovative NEK7-Targeted Molecular Glue Degrader
15 March 2024
Monte Rosa Therapeutics has commenced preclinical trials for its novel compound MRT-8102, a pioneering NEK7-targeted molecular glue degrader with additional capabilities of impeding the NLRP3/IL-1β signaling cascade.
Read →
Tegileridine vs Oliceridine: Comparison of New Analgesic Drugs Targeting Opioid Receptors
Hot Spotlight
7 min read
Tegileridine vs Oliceridine: Comparison of New Analgesic Drugs Targeting Opioid Receptors
15 March 2024
In January, Jiangsu Hengrui Pharmaceuticals' Tegileridine Fumarate injection, for treating moderate to severe post-op abdominal pain, was approved in China.
Read →
FDA Greenlights Aprea's Novel WEE1 Kinase Inhibitor APR-1051 for Cancer Trial
Latest Hotspot
3 min read
FDA Greenlights Aprea's Novel WEE1 Kinase Inhibitor APR-1051 for Cancer Trial
15 March 2024
Aprea Therapeutics reveals it has received FDA authorization for its investigational new drug, APR-1051, a novel WEE1 kinase blocker targeting cancers with high Cyclin E levels.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.